ArticleCell research2016
Pluripotent stem cells induced from mouse neural stem cells and small intestinal epithelial cells by small molecule compounds.
Article in Cell research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Pluripotent stem cells: induction and self-renewal.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Pooled it
- Identification of a Small-Molecule Modulator of Astrocyte Reactivity for Optic Nerve Protection.Investigative ophthalmology & visual science · 2026Article
- Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.Pharmacological reviews · 2025Review
- A rapid chemical reprogramming system to generate human pluripotent stem cells.Nature chemical biology · 2025Article
- Application of induced pluripotent stem cells in the conservation of endangered animals.Stem cell research & therapy · 2025Review
- Chemical-based epigenetic reprogramming to advance pluripotency and totipotency.Nature chemical biology · 2025Review
- From unipotency to pluripotency: deciphering protein networks and signaling pathways in the generation of embryonic stem-like cells from murine spermatogonial stem cells.BMC genomics · 2025Article
- [C6TSEDRVAJZ, a combination of small-molecule compounds, induces differentiation of human placental fibroblasts into epithelioid cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Synergy between pluripotent stem cell-derived macrophages and self-renewing macrophages: Envisioning a promising avenue for the modelling and cell therapy of infectious diseases.Cell proliferation · 2025Review
- Manipulating cell fate through reprogramming: approaches and applications.Development (Cambridge, England) · 2024Review
- Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells.International journal of molecular sciences · 2024Review
- Antiaging Strategies and Remedies: A Landscape of Research Progress and Promise.ACS chemical neuroscience · 2024Review
- Epigenetic reshaping through damage: promoting cell fate transition by BrdU and IdU incorporation.Cell & bioscience · 2024Article
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies.International journal of molecular sciences · 2023Review
- Prediction and Demonstration of Retinoic Acid Receptor Agonist Ch55 as an Antifibrotic Agent in the Dermis.The Journal of investigative dermatology · 2023Article
- Homogeneity of XEN Cells Is Critical for Generation of Chemically Induced Pluripotent Stem Cells.Molecules and cells · 2023Article
- A single cell-based computational platform to identify chemical compounds targeting desired sets of transcription factors for cellular conversion.Stem cell reports · 2023Article
- Stem cell therapy for heart failure in the clinics: new perspectives in the era of precision medicine and artificial intelligence.Frontiers in physiology · 2023Review
- Combination of the modulators of epigenetic machinery and specific cell signaling pathways as a promising approach for cell reprogramming.Molecular and cellular biochemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, we reported a chemical approach to generate pluripotent stem cells from mouse fibroblasts. However, whether chemically induced pluripotent stem cells (CiPSCs) can be derived from other cell types remains to be demonstrated. Here, using lineage tracing, we first verify the generation of CiPSCs from fibroblasts. Next, we demonstrate that neural stem cells (NSCs) from the ectoderm and small intestinal epithelial cells (IECs) from the endoderm can be chemically reprogrammed into pluripotent stem cells. CiPSCs derived from NSCs and IECs resemble mouse embryonic stem cells in proliferation rate, global gene expression profile, epigenetic status, self-renewal and differentiation capacity, and germline transmission competency. Interestingly, the pluripotency gene Sall4 is expressed at the initial stage in the chemical reprogramming process from different cell types, and the same core small molecules are required for the reprogramming, suggesting conservation in the molecular mechanism underlying chemical reprogramming from these diverse cell types. Our analysis also shows that the use of these small molecules should be fine-tuned to meet the requirement of reprogramming from different cell types. Together, these findings demonstrate that full chemical reprogramming approach can be applied in cells of different tissue origins and suggest that chemical reprogramming is a promising strategy with the potential to be extended to more initial types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.